Young-Ae Park1, Chel Hun Choi1, In-Gu Do2, Sang Yong Song2, Jae Kwan Lee3, Young Jae Cho1, Jung-Joo Choi1, Hye Kyung Jeon1, Ji Yoon Ryu1, Yoo-Young Lee1, Tae-Joong Kim1, Duk-Soo Bae1, Jeong-Won Lee4, Byoung-Gie Kim5. 1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 3. Department of Obstetrics and Gynecology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea. 4. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: garden.lee7@gmail.com. 5. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: huna0@naver.com.
Abstract
OBJECTIVE: The renin-angiotensin system (RAS) influences cardiovascular homeostasis, and Angiotensin II type 1 receptor (AGTR1) is the main effector of RAS, and AGTR2 antagonizes AGTR1. Accumulating evidence supports the role of RAS in the paracrine regulation of tumorigenesis in several cancer types. Although treatment with AGTR1 antagonist (losartan) or AGTR2 agonist (CGP42112A) inhibits tumor progression in several cancer cells, their combined treatment has not been reported. METHODS: In this study, we estimated the expression of AGTR1 and AGTR2 in epithelial ovarian cancer cells and tissues. Then, we evaluated the anti-cancer effects of combined treatment with losartan and/or CGP42112A in ovarian cancer cells and human umbilical vein endothelial cells (HUVEC). RESULTS: AGTR1 protein was detected in 86% of ovarian cancer tissues, while AGTR2 was not detected in immunohistochemistry. The mRNA expression of AGTR1 obtained from the cancer genome atlas (TCGA) dataset showed that AGTR1 overexpression was correlated with poor survival. Treatment with either losartan or CGP42112A reduced the angiotensin II (Ang II)-mediated cell survival in both ovarian cancer cells and HUVEC. Combined treatment with losartan and CGP42112A synergistically decreased cell survival. As a downstream pathway, phosphorylation of phospholipase C β3 (PLC β3) and expression of vascular endothelial growth factor (VEGF) decreased synergistically in combined treatment. CONCLUSION: The results suggest that dual regulation of AGTR1 and AGTR2 may be a novel therapeutic strategy for epithelial ovarian carcinoma through inhibition of cancer cell survival as well as anti-angiogenesis. TRANSLATIONAL RELEVANCE: This study investigated the expressions of AGTR1 and AGTR2 in epithelial ovarian carcinoma and the therapeutic potential of AGTR modulation with specific antagonist and/or agonist in epithelial ovarian cancer cells. Treatment of AGTR1 antagonist, losartan and/or AGTR2 agonist, CGP42112A synergistically mediated anti-cancer effects including the decrease of cell survival and down-regulation of VEGF.
OBJECTIVE: The renin-angiotensin system (RAS) influences cardiovascular homeostasis, and Angiotensin II type 1 receptor (AGTR1) is the main effector of RAS, and AGTR2 antagonizes AGTR1. Accumulating evidence supports the role of RAS in the paracrine regulation of tumorigenesis in several cancer types. Although treatment with AGTR1 antagonist (losartan) or AGTR2 agonist (CGP42112A) inhibits tumor progression in several cancer cells, their combined treatment has not been reported. METHODS: In this study, we estimated the expression of AGTR1 and AGTR2 in epithelial ovarian cancer cells and tissues. Then, we evaluated the anti-cancer effects of combined treatment with losartan and/or CGP42112A in ovarian cancer cells and human umbilical vein endothelial cells (HUVEC). RESULTS: AGTR1 protein was detected in 86% of ovarian cancer tissues, while AGTR2 was not detected in immunohistochemistry. The mRNA expression of AGTR1 obtained from the cancer genome atlas (TCGA) dataset showed that AGTR1 overexpression was correlated with poor survival. Treatment with either losartan or CGP42112A reduced the angiotensin II (Ang II)-mediated cell survival in both ovarian cancer cells and HUVEC. Combined treatment with losartan and CGP42112A synergistically decreased cell survival. As a downstream pathway, phosphorylation of phospholipase C β3 (PLC β3) and expression of vascular endothelial growth factor (VEGF) decreased synergistically in combined treatment. CONCLUSION: The results suggest that dual regulation of AGTR1 and AGTR2 may be a novel therapeutic strategy for epithelial ovarian carcinoma through inhibition of cancer cell survival as well as anti-angiogenesis. TRANSLATIONAL RELEVANCE: This study investigated the expressions of AGTR1 and AGTR2 in epithelial ovarian carcinoma and the therapeutic potential of AGTR modulation with specific antagonist and/or agonist in epithelial ovarian cancer cells. Treatment of AGTR1 antagonist, losartan and/or AGTR2 agonist, CGP42112A synergistically mediated anti-cancer effects including the decrease of cell survival and down-regulation of VEGF.
Authors: Richard Perryman; Alexander Renziehausen; Hamidreza Shaye; Androniki D Kostagianni; Antonis D Tsiailanis; Thomas Thorne; Maria V Chatziathanasiadou; Gregory B Sivolapenko; Mohamed Ahmed El Mubarak; Gye Won Han; Barbara Zarzycka; Vsevolod Katritch; Guillaume Lebon; Cristiana Lo Nigro; Laura Lattanzio; Sophie V Morse; James J Choi; Kevin O'Neill; Zoi Kanaki; Apostolos Klinakis; Tim Crook; Vadim Cherezov; Andreas G Tzakos; Nelofer Syed Journal: Proc Natl Acad Sci U S A Date: 2022-08-02 Impact factor: 12.779
Authors: Min Ae Cho; Soo Young Jeong; Insuk Sohn; Myeong-Seon Kim; Jun Hyeok Kang; E Sun Paik; Yoo-Young Lee; Chel Hun Choi Journal: Cancer Res Treat Date: 2020-01-16 Impact factor: 4.679
Authors: Qingyu Zhang; Shan Yu; Melody Man Ting Lam; Terence Chuen Wai Poon; Litao Sun; Yufei Jiao; Alice Sze Tsai Wong; Leo Tsz On Lee Journal: J Exp Clin Cancer Res Date: 2019-03-07
Authors: Ernestina M De Francesco; Federica Sotgia; Robert B Clarke; Michael P Lisanti; Marcello Maggiolini Journal: Int J Mol Sci Date: 2017-12-14 Impact factor: 5.923
Authors: Qingyu Zhang; Nadine Ellen Madden; Alice Sze Tsai Wong; Billy Kwok Chong Chow; Leo Tsz On Lee Journal: Front Endocrinol (Lausanne) Date: 2017-04-07 Impact factor: 5.555